Andere Sprachen LAVA Therapeutics N.V.

Aktien

A2QSJY

NL0015000AG6

LVTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
2.64 ^USD	-3.65%		-6.71%	+67.09%

20.03.	LAVA Therapeutics N.V. berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI
20.03.	LAVA Therapeutics N.V. meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20.03.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20.03.
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20.03.
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)	05.03.
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	05.03.
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	30.01.
Sector Update: Health Care Stocks Softer Late Afternoon	25.01.
Sector Update: Health Care Stocks Slipping Thursday Afternoon	25.01.
Sector Update: Health Care	25.01.
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	25.01.
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	25.01.
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	25.01.
Top Premarket Gainers	25.01.
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®	25.01.
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	25.01.
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	16.11.
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16.11.
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	06.09.23
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	22.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen LAVA Therapeutics N.V.

Aktien

A2QSJY

NL0015000AG6

LVTX

Andere Sprachen

Filter